Geraldes, Carlos F. G. C.; Laurent, Sophie (2009). “Classification and basic properties of contrast agents for magnetic resonance imaging” (英語). Contrast Media & Molecular Imaging4 (1): 1–23. doi:10.1002/cmmi.265. PMID19156706.
Lentschig, M.G.; Reimer, P; Rausch-Lentschig, U.L.; Allkemper, T; Oelerich, M; Laub, G (1998). “Breath-hold gadolinium-enhanced MR angiography of the major vessels at 1.0 T: Dose-response findings and angiographic correlation” (英語). Radiology208 (2): 353–357. doi:10.1148/radiology.208.2.9680558. PMID9680558.
Penfield, Jeffrey G; Reilly, Robert F (2007). “What nephrologists need to know about gadolinium” (英語). Nature Clinical Practice Nephrology3 (12): 654–668. doi:10.1038/ncpneph0660. PMID18033225.
Grobner, T. (2005). “Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?” (英語). Nephrology Dialysis Transplantation21 (4): 1104–1108. doi:10.1093/ndt/gfk062. PMID16431890.
Marckmann, P.; Skov, L; Rossen, K; Dupont, A; Damholt, MB; Heaf, JG; Thomsen, HS (2006). “Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging” (英語). Journal of the American Society of Nephrology17 (9): 2359–2362. doi:10.1681/ASN.2006060601. PMID16885403.
Thomsen, H.S.; Morcos, S.K.; Dawson, P. (2006). “Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?” (英語). Clinical Radiology61 (11): 905–906. doi:10.1016/j.crad.2006.09.003. PMID17018301.
Kanal, E.; Barkovich, A. J.; Bell, C.; Borgstede, J. P.; Bradley, W. G.; Froelich, J. W.; Gilk, T.; Gimbel, J. R. et al. (2007). “ACR Guidance Document for Safe MR Practices: 2007” (英語). American Journal of Roentgenology188 (6): 1447–1474. doi:10.2214/AJR.06.1616. PMID17515363.
Nakamura, Hiroshi; Ito, Naoki; Kotake, Fumio; Mizokami, Yuji; Matsuoka, Takeshi (2000). “Tumor-detecting capacity and clinical usefulness of SPIO-MRI in patients with hepatocellular carcinoma” (英語). Journal of Gastroenterology35 (11): 849–855. doi:10.1007/s005350070022. PMID11085494.
Lin, Yi-Jen; Koretsky, Alan P. (1997). “Manganese ion enhances T1-weighted MRI during brain activation: An approach to direct imaging of brain function” (英語). Magnetic Resonance in Medicine38 (3): 378–388. doi:10.1002/mrm.1910380305. PMID9339438.
Bisset, G. S.; Emery, K. H.; Meza, M. P.; Rollins, N. K.; Don, S.; Shorr, J. S. (1996). “Perflubron as a gastrointestinal MR imaging contrast agent in the pediatric population” (英語). Pediatric Radiology26 (6): 409–415. doi:10.1007/BF01387316. PMID8657479.
Geraldes, Carlos F. G. C.; Laurent, Sophie (2009). “Classification and basic properties of contrast agents for magnetic resonance imaging” (英語). Contrast Media & Molecular Imaging4 (1): 1–23. doi:10.1002/cmmi.265. PMID19156706.
Lentschig, M.G.; Reimer, P; Rausch-Lentschig, U.L.; Allkemper, T; Oelerich, M; Laub, G (1998). “Breath-hold gadolinium-enhanced MR angiography of the major vessels at 1.0 T: Dose-response findings and angiographic correlation” (英語). Radiology208 (2): 353–357. doi:10.1148/radiology.208.2.9680558. PMID9680558.
Penfield, Jeffrey G; Reilly, Robert F (2007). “What nephrologists need to know about gadolinium” (英語). Nature Clinical Practice Nephrology3 (12): 654–668. doi:10.1038/ncpneph0660. PMID18033225.
Grobner, T. (2005). “Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?” (英語). Nephrology Dialysis Transplantation21 (4): 1104–1108. doi:10.1093/ndt/gfk062. PMID16431890.
Marckmann, P.; Skov, L; Rossen, K; Dupont, A; Damholt, MB; Heaf, JG; Thomsen, HS (2006). “Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging” (英語). Journal of the American Society of Nephrology17 (9): 2359–2362. doi:10.1681/ASN.2006060601. PMID16885403.
Centers for Disease Control and Prevention (CDC) (2007). “Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents--St. Louis, Missouri, 2002-2006” (英語). MMWR. Morbidity and Mortality Weekly Report56 (7): 137–141. PMID17318112.
Thomsen, H.S.; Morcos, S.K.; Dawson, P. (2006). “Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?” (英語). Clinical Radiology61 (11): 905–906. doi:10.1016/j.crad.2006.09.003. PMID17018301.
Kanal, E.; Barkovich, A. J.; Bell, C.; Borgstede, J. P.; Bradley, W. G.; Froelich, J. W.; Gilk, T.; Gimbel, J. R. et al. (2007). “ACR Guidance Document for Safe MR Practices: 2007” (英語). American Journal of Roentgenology188 (6): 1447–1474. doi:10.2214/AJR.06.1616. PMID17515363.
Nakamura, Hiroshi; Ito, Naoki; Kotake, Fumio; Mizokami, Yuji; Matsuoka, Takeshi (2000). “Tumor-detecting capacity and clinical usefulness of SPIO-MRI in patients with hepatocellular carcinoma” (英語). Journal of Gastroenterology35 (11): 849–855. doi:10.1007/s005350070022. PMID11085494.
Lin, Yi-Jen; Koretsky, Alan P. (1997). “Manganese ion enhances T1-weighted MRI during brain activation: An approach to direct imaging of brain function” (英語). Magnetic Resonance in Medicine38 (3): 378–388. doi:10.1002/mrm.1910380305. PMID9339438.
Bisset, G. S.; Emery, K. H.; Meza, M. P.; Rollins, N. K.; Don, S.; Shorr, J. S. (1996). “Perflubron as a gastrointestinal MR imaging contrast agent in the pediatric population” (英語). Pediatric Radiology26 (6): 409–415. doi:10.1007/BF01387316. PMID8657479.